Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Peter Boyle

Orthopaedic Surgery Phoenix, AZ Doctor of Osteopathy

NPI 1043647324 CMS profile 2484261

33300 N 32Nd Ave Ste 3200, Phoenix, AZ 85085

Open in the dashboard

General payments

$3,814

35 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Peter Boyle of Phoenix, AZ is reported in the CMS Open Payments database as having received $3,814 across 35 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 51st percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,712 11
2024 General $756 4
2023 General $494 9
2022 General $419 4
2021 General $37 2
2019 General $396 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Peter Boyle
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Peter Boyle were reported at $1,712. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Peter Boyle Orthopaedic Surgery median Middle half National median
2019 $396 $644 $140–$2,844 $163
2020 $0 $312 $75–$1,860 $114
2021 $37 $520 $117–$2,495 $132
2022 $419 $598 $128–$2,731 $149
2023 $494 $461 $128–$2,264 $160
2024 $756 $497 $134–$2,475 $164
2025 $1,712 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $2,001 15 payments
  2. Ortho Development Corporation $867 1 payment
  3. Smith+Nephew, Inc. $697 9 payments
  4. CooperSurgical, Inc. $93 1 payment
  5. Bioventus LLC $50 3 payments
  6. Orthofix Medical, Inc. $38 2 payments
  7. Zimmer Biomet Holdings, Inc. $36 2 payments
  8. Becton, Dickinson and Company $18 1 payment
  9. Kerecis Limited $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $2,441 7 payments
  2. Food and Beverage $1,373 28 payments
Products named General payments · program years 2019–2025
  1. MAKO $1,905 13 payments
  2. REAL INTELLIGENCE $378 4 payments
  3. REDAPT $362 4 payments
  4. JOURNEY II $361 3 payments
  5. TANDEM $325 2 payments
  6. LEGION Revision Recon Knees $325 2 payments
  7. Legion Revision Recon Knees $267 2 payments
  8. Navio Surgical System $267 2 payments
  9. REDAPT Revision Hip System $267 2 payments
  10. Uterine Manipulators & Injectors $93 1 payment
  11. Other $427 22 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

704

Median for Orthopedic Surgery: 203

Drug cost

$3,737

Median for Orthopedic Surgery: $1,433

Branded share of claims

15.2%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone Hcl Generic 162 $1,278
Ondansetron Odt Ondansetron Brand 107 $1,014
Meloxicam Generic 286 $951
Methylprednisolone Generic 43 $337
Amoxicillin Generic 86 $82
Tramadol Hcl Generic 20 $76

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$161,331

Of which drugs: $26,891

Medicare patients

335

Average age 74

Services billed

11,463

207 women, 128 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 73%
Ischemic heart disease 26%
Depression 23%
Diabetes 22%
Chronic kidney disease 22%
Atrial fibrillation 19%
Osteoporosis 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, monovisc, for intra-articular injection, per dose J7327 Office 29 44 $23,772
Injection, methylprednisolone acetate, 1 mg J1010 Office 86 9,840 $1,000
Injection, methylprednisolone acetate, 80 mg J1040 Office 41 49 $338

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

35 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record